{"id":"W4389243535","doi":"10.1182/blood-2023-174432","title":"Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Oncology; Follicular lymphoma; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001145862,0.0002077436,0.0006260247,0.0007216092,0.00008345499,0.00002430854,0.0001198121,0.0001426865,0.00003671338],"category_scores_gemma":[0.0002871043,0.0001818823,0.00008303899,0.001188204,0.00009940076,0.0001205541,0.00009029627,0.0001465804,0.000002551531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001649591,"about_ca_system_score_gemma":0.0002255119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002253434,"about_ca_topic_score_gemma":0.00004616902,"domain_scores_codex":[0.9980177,0.0001221588,0.0005618442,0.0004383147,0.000391519,0.0004684294],"domain_scores_gemma":[0.9990566,0.0003148232,0.0001502457,0.0002938167,0.00007722372,0.0001073113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7678294,0.02179023,0.01384794,0.002677139,0.001119847,0.001359979,0.008219026,0.0001869286,0.1009945,0.0002113145,0.0001355938,0.08162809],"study_design_scores_gemma":[0.8821898,0.01905735,0.02696453,0.00167673,0.0004641484,0.00009403344,0.0002161125,0.004307719,0.06407965,0.0001891585,0.000456046,0.0003047238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930817,0.0003375768,0.00002728772,0.0003317603,0.00002177341,0.005912553,0.000013532,0.00006533125,0.0002084288],"genre_scores_gemma":[0.9973974,0.0002732693,0.0002607083,0.0000182464,0.00003248282,0.0002563385,0.0001610064,0.00005653343,0.001543972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1143604,"threshold_uncertainty_score":0.7416946,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02330380192520908,"score_gpt":0.3039656633172796,"score_spread":0.2806618613920706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}